Condition

ER+ Breast Cancer

ClinicalTrials.gov condition label

Clinical trials25

Recruiting12

Common interventions25

Lead sponsors shown15

Clinical trials

25 shown

Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence.NCT07443774 · 2026-05-26

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast CancerNCT07483307 · 2026-03-13

Breast Re-irradiation After Second Ipsilateral LumpectomyNCT06867484 · 2025-10-27

Circulating Tumor DNANCT06923527 · 2025-09-30

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCNCT07002177 · 2025-06-01

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.NCT06590857 · 2024-07-19

Breast Cancer Evolution During Neoadjuvant Systemic TherapyNCT06681064 · 2024-05-29

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesNCT06395519 · 2024-05-13

JAB-2485 Activity in Adult Patients With Advanced Solid TumorsNCT05490472 · 2022-12-20

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast CancerNCT05534438 · 2022-09-06

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerNCT04985266 · 2022-03-30

4FMFES-PET Imaging of ER+ Advanced Breast CancersNCT04824014 · 2020-11-01

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast CancerNCT06407401 · 2024-12-01

NOT_YET_RECRUITING

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614 · 2023-03-24

Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionNCT04920708 · 2022-12-28

ACTIVE_NOT_RECRUITING

Tamoxifen Prediction Study in Patients With ER+ Breast CancerNCT05525481 · 2022-11-01

Alcohol and Breast Cancer (ABC) TrialNCT05423730 · 2022-09-01

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)NCT04551495 · 2021-01-14

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerNCT04360941 · 2020-08-11

ACTIVE_NOT_RECRUITING

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.NCT03983954 · 2019-10-10

ACTIVE_NOT_RECRUITING

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen LevelsNCT04312347 · 2019-09-06

CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)NCT02580448 · 2015-08-01

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer PatientsNCT01202591 · 2010-12-01

Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is ProgressingNCT00828854 · 2008-10-01

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast CancerNCT00676663 · 2008-06-13

Common interventions

Leading sponsors

Royal Marsden NHS Foundation Trust4 Memorial Sloan Kettering Cancer Center2 Syndax Pharmaceuticals2 858 Therapeutics, Inc.1 AstraZeneca1 Beth Israel Deaconess Medical Center1 Boundless Bio, Inc.1 Centre de recherche du Centre hospitalier universitaire de Sherbrooke1 Erasmus Medical Center1 European Organisation for Research and Treatment of Cancer - EORTC1 Forward Pharmaceuticals Co., Ltd.1 Innocrin Pharmaceutical1 Jacobio Pharmaceuticals Co., Ltd.1 Jules Bordet Institute1 Nalagenetics Pte Ltd1

Trial status mix

RECRUITING12

COMPLETED6

ACTIVE_NOT_RECRUITING3

UNKNOWN2

NOT_YET_RECRUITING1

TERMINATED1

Phase mix

PHASE215

PHASE19

NA3

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.